UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

Journal of palliative medicine, 2013-06, Vol.16 (6), p.623-631

2013

Volltextzugriff (PDF)

γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2), p.573-582

2009

Volltextzugriff (PDF)

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Investigational new drugs, 2021-02, Vol.39 (1), p.163-174

2021

Volltextzugriff (PDF)

The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis

Molecular therapy, 2000-02, Vol.1 (2), p.130-144

2000

Volltextzugriff (PDF)

p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin

International journal of oncology, 1999-01, Vol.14 (1), p.5

1999

Volltextzugriff (PDF)

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT328-CT328

2014

Volltextzugriff (PDF)

JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4147-TPS4147

2014

Volltextzugriff (PDF)

p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ

Experimental cell research, 2001-01, Vol.262 (2), p.154-169

2001

Volltextzugriff (PDF)

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5017-5017

2016

Volltextzugriff (PDF)

A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS2616-TPS2616

2012

Volltextzugriff (PDF)

Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo

Urologic oncology, 2001-07, Vol.6 (4), p.155-162

2001

Volltextzugriff (PDF)

A randomized trial of a cardiopulmonary resuscitation (CPR) video (V) in advance care planning (ACP) for progressive hepatopancreaticobiliary cancer patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.9105-9105

2012

Volltextzugriff (PDF)

Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression

Clinical cancer research, 1998-01, Vol.4 (1), p.251-259

1998

Volltextzugriff (PDF)

Comparative Gene Expression Profiling in Response to p53 in a Human Lung Cancer Cell Line

Biochemical and biophysical research communications, 1999-11, Vol.264 (3), p.891-895

1999

Volltextzugriff (PDF)

"p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999

Journal of Cellular Physiology, 1999, Vol.181 (2), p.371-374

1999

Volltextzugriff (PDF)

"p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999

Journal of cellular physiology, 1999-11, Vol.181 (2), p.371-374

1999

Volltextzugriff (PDF)

Tumor suppressor gene therapy for cancer: from the bench to the clinic

Drug resistance updates, 1998, Vol.1 (3), p.205-210

1998

Volltextzugriff (PDF)

The TRAIL decoy receptor TRUNDD ( DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/ DR5-dependent colon cancer apoptosis

Meng, Raymond D

2001

Volltextzugriff (PDF)

The Circadian Clock in Murine Chondrocytes Regulates Genes Controlling Key Aspects of Cartilage Homeostasis

Arthritis & rheumatology (Hoboken, N.J.), 2013-09, Vol.65 (9), p.2334-2345

2013

Volltextzugriff (PDF)

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-03, Vol.38 (7), p.706-714

2020

Volltextzugriff (PDF)

The intervertebral disc contains intrinsic circadian clocks that are regulated by age and cytokines and linked to degeneration

Annals of the rheumatic diseases, 2017-03, Vol.76 (3), p.576-584

2017

Volltextzugriff (PDF)

Demonstration of an Electrochemical Liquid Cell for Operando Transmission Electron Microscopy Observation of the Lithiation/Delithiation Behavior of Si Nanowire Battery Anodes

Nano letters, 2013-12, Vol.13 (12), p.6106-6112

2013

Volltextzugriff (PDF)

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort

The Journal of urology, 2016-02, Vol.195 (2), p.313-320

2016

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(107)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis

p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors

JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma

p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)

A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate

Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo

A randomized trial of a cardiopulmonary resuscitation (CPR) video (V) in advance care planning (ACP) for progressive hepatopancreaticobiliary cancer patients

Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression

Comparative Gene Expression Profiling in Response to p53 in a Human Lung Cancer Cell Line

"p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999

"p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999

Tumor suppressor gene therapy for cancer: from the bench to the clinic

The TRAIL decoy receptor TRUNDD ( DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/ DR5-dependent colon cancer apoptosis

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

The Circadian Clock in Murine Chondrocytes Regulates Genes Controlling Key Aspects of Cartilage Homeostasis

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer

The intervertebral disc contains intrinsic circadian clocks that are regulated by age and cytokines and linked to degeneration

Demonstration of an Electrochemical Liquid Cell for Operando Transmission Electron Microscopy Observation of the Lithiation/Delithiation Behavior of Si Nanowire Battery Anodes

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort

Suchergebnisse filtern